Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :713
Small font sizeDefault font sizeIncrease font size
Resource Links
     Search Pubmed for
 
    -  Sahinli H
    -  Akyürek N
    -  Yılmaz M
    -  Kandemir O
    -  Duran AO
    -  Kulaçoğlu S
    -  Uçar G
    -  Acar E
    -  Özet A
    -  Gümüş M
    -  Ç. Öksüzoğlu &B
    -  Özdemir NY
 

 Article Access Statistics
    Viewed728    
    PDF Downloaded26    

Recommend this journal

 

 ORIGINAL ARTICLE

PD-L1 expression in immune cells is a favorable prognostic factor for nasopharyngeal carcinoma


1 Department of Oncology, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
2 Department of Pathology, Gazi University Medical Hospital, Ankara, Turkey
3 Department of Oncology, Gazi University Medical University Hospital, Ankara, Turkey
4 Department of Pathology, Dr. Abdurrahman Yurtaslan Ankara Oncology Hospital, Ankara, Turkey
5 Department of Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Hospital, Ankara, Turkey
6 Department of Pathology, Ankara Numune Training and Research Hospital, Ankara, Turkey
7 Department of Oncology, Ankara Numune Training and Research Hospital, Ankara, Turkey
8 Department of Oncology, Medical School of Istanbul Medipol University, Istanbul, Turkey

Correspondence Address:
Hayriye Sahinli,
Department of Oncology, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara
Turkey
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijc.IJC_459_19

PMID: 33402600

Background: Programmed death-ligand 1 (PD-L1) has been determined as a reliable prognostic factor for various malignancies. In this study, we aimed to determine the prognostic effect of PD-L1 expression in tumor-infiltrating immune cells (TIICs) of nasopharyngeal carcinoma (NPC) patients. Methods: Seventy patients diagnosed with non-metastatic NPC were included in the study. PD-L1 expression on immune cells was analyzed by immunohistochemical method. Patients were categorized into two groups according to the PD-L1 expression level in TIICs (level of PD-L1 staining ≥5% positive vs <5% negative). Results: Median follow-up period was 34 months (range = 1 - 188). 1 and 2 years survival rate were found as 75% and 63% in PD-L1 negative TIICs group (47%), and 85% and 83% in PD-L1 positive TIICs group (53%), respectively. PD-L1 positivity in immune cells (ICs) was detected in 53% of the patients. The survival rate was found better in the PD- L1 positive group compared to the negative group (P = 0.049). Discussion: In conclusion, the survival rate was found significantly better in the PD-L1 positive TIICs group, compared to the negative group.




  Site Map | What's new | Copyright and Disclaimer
  Online since 1st April '07
  2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow